← Claudine Duvivier

Papers by Claudine Duvivier

Page 1 · newest first

1. Efficacy and safety of switching to once-daily oral doravirine plus raltegravir in virologically suppressed people with HIV-1: a randomized, open-label, multicentre phase 2 study (DORAL)Journal of Antimicrobial Chemotherapy · 2026
2. Lenacapavir Use in France: A National, Observational Study (LENAddOn)Open Forum Infectious Diseases · 2026
3. Efficacy and safety of lenacapavir containing regimens in highly experienced HIV-infected patients with multidrug-resistance: real-word results from the French Compassionate Use ProgramOpen Forum Infectious Diseases · 2026
4. Switching from etravirine to doravirine in virologically suppressed people with HIV: results from the French multicentre SWEED observational studyJournal of Antimicrobial Chemotherapy · 2025
5. Association between late access to care and mortality for PWH: insights from the French Hospital Database on HIV (ANRS CO4-FHDH) from 2002 to 2016BMJ Public Health · 2025
6. Real-world effectiveness, safety, and health-related quality of life in people living with HIV receiving bictegravir/emtricitabine/tenofovir alafenamide—12-month results of the BICSTaR French cohortIJID Regions · 2025
7. Low CD4 Cell Count Is Associated With Post–Hepatitis C Virus Cure Mortality in People With HIV (ANRS CO13 HEPAVIH Cohort)Clinical Infectious Diseases · 2025
8. Correlates of mental health of people living with HIV co-infected with SARS-CoV-2: findings from the COVIDHIV study in FranceFrontiers in Psychiatry · 2025
9. Engagement in Preexposure Prophylaxis Care at 1 Year Among Men Who Have Sex With Men Enrolled in the French ANRS PREVENIR Cohort StudyOpen Forum Infectious Diseases · 2024
10. Acceptability determinants of a proposal to reduce antiretroviral treatment to an oral two-drug regimen among patients living with HIV and physicians in FrancePLoS ONE · 2024
11. Increased incidence of diabetes in people living with HIV treated with first‐line integrase strand transfer inhibitors: A French multicentre retrospective studyHIV Medicine · 2024
12. High proportion of post-migration HIV acquisition in migrant men who have sex with men receiving HIV care in the Paris region, and associations with social disadvantage and sexual behaviours: results of the ANRS-MIE GANYMEDE study, France, 2021 to 2022Eurosurveillance · 2024
13. Differences in integrated assessment and management of non‐communicable diseases (NCDs) for people with HIV across the WHO European regionHIV Medicine · 2024
14. Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug-Resistant Human Immunodeficiency Virus Type 2 InfectionClinical Infectious Diseases · 2023
15. Proportion of APOBEC3-induced defective HIV DNA after 1 year of dolutegravir + lamivudine simplification in the ANRS 167 LAMIDOL trialJournal of Antimicrobial Chemotherapy · 2023
16. Country of birth is associated with discrepancies in the prescription of two-drug regimens in successfully treated people with HIV in FranceAIDS · 2023
17. Maintenance darunavir/ritonavir monotherapy to prevent perinatal HIV transmission, ANRS-MIE 168 MONOGEST studyJournal of Antimicrobial Chemotherapy · 2023
18. Four days/week antiretroviral maintenance strategy (ANRS 170 QUATUOR): substudies of reservoirs and ultrasensitive drug resistanceJournal of Antimicrobial Chemotherapy · 2023
19. Country of birth is associated with antiretroviral therapy choice in treatment-naive persons with HIV in FranceAIDS · 2023
20. Mortality in hepatitis C virus-cured vs. hepatitis C virus-uninfected people with HIVAIDS · 2023
21. Weight gain following the single substitution of tenofovir disoproxil fumarate by tenofovir alafenamide in HIV‐infected people from the French Dat'AIDS cohort: A propensity score‐matched analysisHIV Medicine · 2023
22. Low-level viral loads and virological failure in the integrase strand transfer eraJournal of Antimicrobial Chemotherapy · 2023
23. Striking differences in weight gain after cART initiation depending on early or advanced presentation: results from the ANRS CO4 FHDH cohortJournal of Antimicrobial Chemotherapy · 2023
24. Same-day initiation of bictegravir/emtricitabine/tenofovir alafenamide: Week 48 results of the FAST study—IMEA 055Journal of Antimicrobial Chemotherapy · 2023
25. Depressive symptoms after hepatitis C cure and socio-behavioral correlates in aging people living with HIV (ANRS CO13 HEPAVIH)JHEP Reports · 2022
26. Impact on renal function of daily and on-demand HIV pre-exposure prophylaxis in the ANRS-PREVENIR studyJournal of Antimicrobial Chemotherapy · 2022
27. Observational cohort study of rilpivirine (RPV) utilization in EuropeAIDS Research and Therapy · 2022
28. High syphilis prevalence and incidence in people living with HIV and Preexposure Prophylaxis users: A retrospective review in the French Dat’AIDS cohortSHILAP Revista de lepidopterología · 2022
29. Incidence of cervical, breast and colorectal cancers between 2010 and 2015 in people living with HIV in FrancePLoS ONE · 2022
30. HCV cure: an appropriate moment to reduce cannabis use in people living with HIV? (ANRS CO13 HEPAVIH data)AIDS Research and Therapy · 2022
31. Pneumocystis jirovecii Pneumonia and Toxoplasmosis in PWH With HIV-Controlled Disease Treated for Solid Malignancies: A DAT’AIDS StudyOpen Forum Infectious Diseases · 2022
32. The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA studyHIV Medicine · 2021
33. HCV reinfection after HCV therapy among HIV/HCV‐coinfected individuals in EuropeHIV Medicine · 2021
34. No increased risk of Kaposi sarcoma relapse in patients with controlled HIV‐1 infection after switching protease inhibitor‐based antiretroviral therapyHIV Medicine · 2021
35. Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life settingJournal of Antimicrobial Chemotherapy · 2021
36. Trends in asymptomatic STI among HIV-positive MSM and lessons for systematic screeningPLoS ONE · 2021
37. Factors Associated With Being Overweight and Obesity in People Living With Human Immunodeficiency Virus on Antiretroviral Therapy: Socioclinical, Inflammation, and Metabolic MarkersThe Journal of Infectious Diseases · 2021
38. Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment–Experienced People Living With Human Immunodeficiency VirusClinical Infectious Diseases · 2020
39. Spectrum and Incidence Trends of AIDS- and Non–AIDS-Defining Cancers between 2010 and 2015 in the French Dat'AIDS CohortCancer Epidemiology Biomarkers & Prevention · 2020
40. Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimenJournal of Antimicrobial Chemotherapy · 2020
41. Atherosclerotic Cardiovascular Events in Patients Infected With Human Immunodeficiency Virus and Hepatitis C VirusClinical Infectious Diseases · 2020
42. Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral‐naïve persons starting treatmentHIV Medicine · 2020
43. Post‐exposure prophylaxis completion and condom use in the context of potential sexual exposure to HIV*HIV Medicine · 2020
44. Risk of Severe Bacterial Infection in People Living Human Immunodeficiency Virus Infection in the Combined Antiretroviral Therapy EraThe Journal of Infectious Diseases · 2020
45. Kaposi sarcoma among people living with HIV in the French DAT’AIDS cohort between 2010 and 2015Journal of the European Academy of Dermatology and Venereology · 2020
46. Multimorbidity in Elderly Persons According to the Year of Diagnosis of Human Immunodeficiency Virus Infection: A Cross-sectional Dat’AIDS Cohort StudyClinical Infectious Diseases · 2019
47. Kaposi sarcoma in people living with HIV: incidence and associated factors in a French cohort between 2010 and 2015AIDS · 2019
48. Virological and immunological impact of integrase inhibitor-based regimens initiated during primary HIV-1 infectionAIDS · 2019
49. Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIVThe Journal of Infectious Diseases · 2019
50. Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infectionPLoS ONE · 2019